The Next Evolution of the JOST KKS Automatic Coupling System: the KKS-U Connector
16.5.2023 11:00:00 EEST | Business Wire | Press release
In April 2021 JOST introduced the revolutionary KKS automatic coupling system. It enables the driver to couple and uncouple the semi-trailer via remote control – automatically, safely and quickly. Climbing out of the cabin, cranking down the landing gear and manually connecting the spiral cable, air and brake connections are all a thing of the past. Now JOST presents the latest development of the KKS: the KKS-U Connector which is retrofittable to existing trailers that already are on the roads of this world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230516005001/en/
The KKS-U Connector is easily retrofittable to trailers that are already in use. (Photo: JOST)
Coupling and uncoupling a trailer is still a lengthy, expensive and hazardous procedure. The truck driver has to be aware of many different things, each of which are time-consuming and pose a hazard to health and safety. As the global market leader for fifth wheel couplings and landing gears, JOST is providing a smart solution for the future of coupling with its KKS automatic coupling system. The KKS 42 fifth wheel coupling, Modul E-Drive electric landing gear, sensor coupling system, 3-sensors, LubeTronic automatic lubrication system, KKS remote control and the ISO 13044-2-certified KKS connector all combine to form an innovative system for the coupling process.
KKS-U Connector retrofittable to existing trailers
Until now the KKS was a solution for mixed fleets and new trailers. JOST has now further developed the system and is introducing the new KKS-U Connector to the market. Fitted to the underside of the trailer, the KKS-U Connector is an alternative installation variant and enables fleet operators to equip existing trailers easily with the KKS. It connects all the mechanical, electric, and air connections between the truck and trailer, eliminating the need for the standard vulnerable air, electrics and ABS/EBS spiral lines.
The KKS-U basically consists of three parts: the reliable future-proof and ISO 13044-2 compliant standard wedge, the steel spring and the cable box. The newly designed wedge has the familiar KKS connector installed inside. It is attached to the high-quality JOST king pin and rotates around it when cornering. The steel spring encases the supply lines for air, brake and electric safely and reliably. The supply lines are safely stowed in the KKS cable box and are fed into the steel spring when cornering.
“The KKS-U Connector is a unique solution for all trailers that are already in operation. Due to a particularly straightforward installation, they can be effortlessly equipped with the KKS system. No modifications to the trailer chassis are necessary”, said Andreas Jakubin, Product Manager KKS. “Thus, the KKS-U contributes to further savings in time and expenses as well as avoidance of accidents.”
Advantages of the KKS: more efficiency and safety for truck drivers
Using the KKS automatic coupling system can cut the time required to change a trailer by up to 50 percent, as there is no need to manually crank the landing gear, connect the supply lines or open the fifth wheel coupling. The KKS significantly reduces the total costs for each circuit, with savings of up to 50 percent possible during the coupling and uncoupling process. It is particularly well suited for transport companies which perform coupling processes often and drive short distances, such as those in on-site transport, as the time saved here really pays off financially. Another application is the transport of goods where safety plays a key role, such as hazardous goods, as the sensor monitoring guarantees a high level of security against trailer losses and incorrect coupling. The KKS is also an ideal solution for transport between production sites and logistics facilities. Errors or damage caused during the coupling process are eliminated completely thanks to monitoring through the KKS remote control. For example, the Modul E-Drive landing gear is always fully retracted automatically. Moreover, the KKS reduces the probability of trailer losses due to erroneous operation, damage and occupational accidents to virtually zero.
Furthermore, the KKS makes all the physically demanding tasks of the coupling process a thing of the past, as well as ensuring that this process is no longer dependent on the weather or time of day and significantly reducing stress. A standard pneumatic cylinder opens the fifth wheel coupling effortlessly, even when the tractor-trailer is twisted. The automatic coupling process means that the driver does not have to climb in and out of the cab as often, nor climb onto the catwalk between truck and semi-trailer – two factors that significantly reduce the potential for injury. These benefits mean the KKS opens new possibilities for a more diverse driver pool; as such, JOST is providing an answer to demographic change and the lack of specialist workers.
More information on the KKS and KKS-U Connector online at: kks-futurenow.com
About JOST:
JOST is a world-leading producer and supplier of safety-critical systems for the commercial vehicle industry. Under the umbrella brand of JOST, the comprehensive range of products is broken down into systems for applications on the road and in agriculture:
The JOST brand includes fifth wheel couplings, landing gears, ball bearing turntables, king pins and container locks as well as components for alternating systems. Truck and trailer axles are also sold under the JOST brand. The tradition-steeped ROCKINGER brand comprises the core components of towing hitches, drawbar eyes and drawbars for transporters and trucks. TRIDEC offers steering systems and axle suspensions for trailers.
ROCKINGER products are also used in agricultural applications. Quicke has been part of the JOST family since February 2020 and specialises in agricultural front loaders and equipment.
JOST currently employs over 3,600 staff worldwide and has sales and production sites in over 20 countries and on all five continents. JOST has been listed on the Frankfurt Stock Exchange. Further information on JOST can be found here: www.jost-world.com
Press images can be found here: https://www.jost-world.com/en/corporate/mediacenter/press-releases.html
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230516005001/en/
Contact information
Christin Zindritsch
Manager Marketing Communications
christin.zindritsch@jost-world.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom